The programme will start with a pilot phase at the Nasser Institute Hospital in Cairo, serving as the testing ground for Egypt’s first robotic surgical system in the public sector.
Egypt currently runs 175 stroke units, comprising 113 primary facilities and 62 comprehensive centers.
As part of AAIB’s corporate social responsibility efforts, the system draws on cutting-edge global oncology technology.
The procedures took place at Al-Nasr Specialised Hospital in Port Said, representing a major advancement in accessible cardiac care for Egyptian citizens.
These investments aim to elevate the standard of care available to patients while positioning Alameda as a provider of choice for complex medical procedures.
The guide covers cardiac and thoracic surgeries, interventional radiology procedures, and comprehensive care for conditions such as multiple sclerosis.
The strategic focus will center on three key areas: enhancing the product portfolio, accelerating digital transformation and e-commerce capabilities, and driving expansion into regional markets across the Middle East and Africa.
The hospital’s infrastructure includes approximately 240 patient rooms, 48 intensive care beds, seven operating theatres, and two catheterisation laboratories, enabling staff to deliver care across more than 40 specialized medical disciplines.
The partnership specifically targets the domestic manufacture of PCV13 using VACSERA’s established production facilities and infrastructure within Egypt.
The medical city will occupy 221 feddan of land and incorporate 18 distinct specialized institutes, creating a comprehensive healthcare ecosystem.